Эпидемиологическое значение бессимптомных носителей COVID-19
https://doi.org/10.31631/2073-3046-2020-19-6-69-73
Аннотация
Актуальность. Пандемия новой коронавирусной инфекции является серьезным испытанием для мировой системы здравоохранения, а контроль за развитием эпидемического процесса одна из главных задач в борьбе с COVID-19. Цель. По данным зарубежной литературы оценить роль бессимптомных носителей COVID-19 в эпидемическом процессе новой коронавирусной инфекции. Выводы. Показано менее стойкое формирование иммунного ответа у лиц с бессимптомной формой заболевания по сравнению клиническими формами инфекции COVID-19. Для выяснения аспектов патогенетического процесса и установления реальной стойкости иммунного ответа помимо исследования гуморального иммунного ответа целесообразно изучение клеточного звена иммунитета, в особенности клеток памяти у лиц, перенесших COVID-19. С целью подбора наиболее оптимальных противоэпидемических мер для сдерживания дальнейшего распространения заболевания, в том числе бессимптомного носительства необходимо установление индекса репродукции и определение минимальной инфицирующей дозы SARS-CoV-2.
Об авторах
Е. А. Базыкина
Хабаровский научно-исследовательский институт эпидемиологии и микробиологии Роспотребнадзора
Россия
Россия
Базыкина Елена Анатольевна - младший научный сотрудник Хабаровского НИИ эпидемиологии и микробиологии.
Хабаровск.
Тел. +7 (4212) 46-18-55
О. Е. Троценко
Хабаровский научно-исследовательский институт эпидемиологии и микробиологии Роспотребнадзора
Россия
Россия
Троценко Ольга Евгеньевна – доктор медицинских наук, директор Хабаровского НИИ эпидемиологии и микробиологии.
Хабаровск.
Тел. +7(4212)32-52-28
Список литературы
1. Al-Tawfiq JA. Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19). Travel Med Infect Dis. 2020;35:101608. doi:10.1016/j.tmaid.2020.101608.
2. Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol immunol infect. 2020;53(3):404-412. doi:10.1016/j.jmii.2020.02.012.
3. Gao Z, Xu Y, Sun C, et al. A Systematic Review of Asymptomatic Infections with COVID-19. J Microbiol Immunol Infect. 2020;10.1016/j.jmii.2020.05.001. doi:10.1016/j.jmii.2020.05.001
4. Wu ZY. Contribution of asymptomatic and pre-symptomatic cases of COVID-19 in spreading virus and targeted control strategies. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(6):801-805. Chinese. doi: 10.3760/cma.j.cn112338-20200406-00517. PMID: 32274917.
5. Wu Z, McGoogan JM. Asymptomatic and Pre-Symptomatic COViD-19 in China. infect Dis Poverty. 2020;9(1):72. doi:10.1186/s40249-020-00679-2.
6. Huff HV, Singh A. Asymptomatic transmission during the COViD-19 pandemic and implications for public health strategies. Clin infect Dis. 2020;ciaa654. doi:10.1093/cid/ciaa654.
7. Lin C, Ding Y, Xie B, et al. Asymptomatic novel coronavirus pneumonia patient outside Wuhan: The value of CT images in the course of the disease. Clin imaging. 2020;63:7-9. doi:10.1016/j.clinimag.2020.02.008.
8. Castanheira J, Mascarenhas Gaivao A, Mairos Teixeira S, et al. Asymptomatic COViD-19 positive patient suspected on FDG-PET/CT. Nucl Med Commun. 2020;41(6):598-599. doi:10.1097/MNM.0000000000001221.
9. Albano D, Bertagna F, Bertoli M, et al. incidental Findings Suggestive of COVID-19 in Asymptomatic Patients Undergoing Nuclear Medicine Procedures in a High-Prevalence Region. J Nucl Med. 2020;61(5):632-636. doi:10.2967/jnumed.120.246256.
10. Meng H, Xiong R, He R, et al. CT imaging and clinical course of asymptomatic cases with COViD-19 pneumonia at admission in Wuhan, China. J infect. 2020;81(1):e33-e39. doi:10.1016/j.jinf.2020.04.004.
11. Yu X, Yang R. COViD-19 transmission through asymptomatic carriers is a challenge to containment. influenza Other Respir Viruses. 2020;14(4):474-475. doi:10.1111/irv.12743.
12. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 infection: A Narrative. Ann intern Med. 2020;M20-3012. doi:10.7326/M20-3012.
13. Hosoki K, Chakraborty A, Sur S. Molecular mechanisms and epidemiology of COViD-19 from an allergist's perspective. J Allergy C!in immuno!. 2020;S0091-6749(20)30799-5. doi:10.1016/j.jaci.2020.05.033.
14. Wei L, Lin J, Duan X, et al. Asymptomatic COViD-19 Patients Can Contaminate Their Surroundings: an Environment Sampling Study. mSphere. 2020;5(3):e00442-20. doi:10.1128/mSphere.00442-20.
15. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020;323(14):1406-1407. doi:10.1001/jama.2020.2565;
16. Huang L, Zhang X, Zhang X, et al. Rapid asymptomatic transmission of COViD-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COViD-19: A prospective contact-tracing study. J infect. 2020;80(6):e1-e13. doi:10.1016/j.jinf.2020.03.006.
17. Ye F, Xu S, Rong Z, et al. De!ivery of infection from asymptomatic carriers of COViD-19 in a familial cluster. int J infect Dis. 2020;94:133-138. doi:10.1016/j.ijid.2020.03.042.
18. Pan X, Chen D, Xia Y, et al. Asymptomatic cases in a family cluster with SARS-CoV-2 infection. Lancet Infect Dis. 2020;20(4):410-411. doi:10.1016/S1473-3099(20)30114-6ю
19. Gao M, Yang L, Chen X, et al. A study on infectivity of asymptomatic SARS-CoV-2 carriers. Respir Med. 2020;169:106026. doi:10.1016/j.rmed.2020.106026
20. He D, Zhao S, Lin Q, et al. The relative transmissibility of asymptomatic COViD-19 infections among close contacts. int J infect Dis. 2020;94:145-147. doi:10.1016/j.ijid.2020.04.034.
21. Chen Y, Wang A, Yi B, et al. The epidemiological characteristics of infection in close contacts of COViD-19 in Ningbo city. Chin J Epidemiol. 2020:41.
22. Miyamae Y, Hayashi T, Yonezawa H, et al. Duration of viral shedding in asymptomatic or mild cases of novel coronavirus disease 2019 (COVID-19) from a cruise ship: A singlehospital experience in Tokyo, Japan. int J infect Dis. 2020;97:293-295. doi:10.1016/j.ijid.2020.06.020.
23. Li W, Su YY, Zhi SS, et al. Viral shedding dynamics in asymptomatic and mildly symptomatic patients infected with SARS-CoV-2. Clin Microbiol infect. 2020;S1198-743X(20)30410-9. doi:10.1016/j.cmi.2020.07.008.
24. Wu Z, McGoogan JM. Asymptomatic and Pre-Symptomatic COViD-19 in China. infect Dis Poverty. 2020;9(1):72. doi:10.1186/s40249-020-00679-2.
25. National Health Commission of the People's Republic of China. Update on COVID-19 in China as of 24th hour on April 7,2020. Beijing, China: National Health Commission;2020.
26. Kim GU, Kim MJ, Ra SH, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol infect. 2020;26(7):948.e1-948.e3. doi:10.1016/j.cmi.2020.04.040.
27. Pollan M, Pёrez-Gбmez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;S0140-6736(20)31483-5. doi:10.1016/S0140-6736(20)31483-5.
28. Gallian P, Pastorino B, Morel P, et al. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood. Antiviral Res. 2020;181:104880. doi:10.1016/j.antiviral.2020.104880.
29. Rivett L, Sridhar S, Sparkes D, et al. Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. Elife. 2020;9:e58728. doi:10.7554/eLife.58728.
30. Korth J, Wilde B, Dolff S, et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. J Clin Virol. 2020;128:104437. doi:10.1016/j.jcv.2020.104437.
31. Schmidt SB, Grdter Boltzmann M, Rollnik JD. Prevalence of serum IgG antibodies against SARS-CoV-2 among clinic staff. PLoS One. 2020;15(6):e0235417. doi:10.1371/journal.pone.0235417.
32. Garcia-Basteiro AL, Moncunill G, Tortajada M, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11(1):3500. doi:10.1038/s41467-020-17318-x.
33. Corradini P, Gobbi G, de Braud F, et al. Rapid Antibody Testing for SARS-CoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections. Hemasphere. 2020;4(3):e408. doi:10.1097/HS9.0000000000000408.
34. Patel MC, Chaisson LH, Borgetti S, et al. Asymptomatic SARS-CoV-2 infection and COVID-19 mortality during an outbreak investigation in a skilled nursing facility. Clin Infect Dis. 2020;ciaa763. doi:10.1093/cid/ciaa763.
35. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. N Engl J Med. 2020;382(22):2158-2160. doi:10.1056/NEJMe2009758.
36. Nahshon C, Bitterman A, Haddad R, et al. Hazardous Postoperative Outcomes of Unexpected COVID-19 Infected Patients: A Call for Global Consideration of Sampling all Asymptomatic Patients Before Surgical Treatment. World J Surg. 2020;44(8):2477-2481. doi:10.1007/s00268-020-05575-2.
37. Siracusano G, Pastori C, Lopalco L. Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art. Front Immunol. 2020;11:1049. doi:10.3389/fimmu.2020.01049.
38. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;10.1038/s41591-020-0965-6. doi:10.1038/s41591-020-0965-6.
39. Choe PG, Kang CK, Suh HJ, et al. Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients. Emerg Infect Dis. 2020;26(10):10.3201/ eid2610.202211. doi:10.3201/eid2610.202211.
40. Siracusano G, Pastori C, Lopalco L. Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art. Front Immunol. 2020;11:1049. doi:10.3389/fimmu.2020.01049.
41. Spiegel, M., Pichlmair, A., Martfnez-Sobrido, L., et al. Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3. J Virol 2005. 79: 2079-2086.
42. Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio Oct 2018, 9 (5) e01753-18. doi:10.1128/mBio.01753-18.
43. Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Sci Immunol. 2020;5(49):eabd6160. doi:10.1126/sciimmunol.abd6160.
Рецензия
Для цитирования:
Базыкина Е.А., Троценко О.Е. Эпидемиологическое значение бессимптомных носителей COVID-19. Эпидемиология и Вакцинопрофилактика. 2020;19(6):69-73. https://doi.org/10.31631/2073-3046-2020-19-6-69-73
For citation:
Bazykina E.A., Trotsenko O.E. Epidemiological Significance of Asymptomatic Carriers of COVID-19. Epidemiology and Vaccinal Prevention. 2020;19(6):69-73. (In Russ.) https://doi.org/10.31631/2073-3046-2020-19-6-69-73
Просмотров: 756
Послать статью по эл. почте 